Pharmacy Times October 9, 2025
Edgar Asebey, ESQ., Danielle Valletti, Assistant Editor

Pharmaceutical companies navigate FDA regulations and explore AI solutions to enhance compliance in drug advertising and enforcement.

In this Pharmacy Times interview, Edgar Asebey, Esq., FDA regulatory attorney at Frier Levitt, discusses how artificial intelligence (AI) could transform FDA enforcement and oversight of direct-to-consumer (DTC) advertising. He explains that as pharmaceutical advertising budgets have surged since the late 1990s, the FDA’s compliance responsibilities have...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, FDA, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1)

Share Article